These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

490 related items for PubMed ID: 20096389

  • 1. Chitosan-based nanoparticles for improving immunization against hepatitis B infection.
    Prego C, Paolicelli P, Díaz B, Vicente S, Sánchez A, González-Fernández A, Alonso MJ.
    Vaccine; 2010 Mar 19; 28(14):2607-14. PubMed ID: 20096389
    [Abstract] [Full Text] [Related]

  • 2. Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen.
    Borges O, Silva M, de Sousa A, Borchard G, Junginger HE, Cordeiro-da-Silva A.
    Int Immunopharmacol; 2008 Dec 20; 8(13-14):1773-80. PubMed ID: 18801462
    [Abstract] [Full Text] [Related]

  • 3. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
    Gupta NK, Tomar P, Sharma V, Dixit VK.
    Vaccine; 2011 Nov 08; 29(48):9026-37. PubMed ID: 21939718
    [Abstract] [Full Text] [Related]

  • 4. Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles.
    Borges O, Cordeiro-da-Silva A, Tavares J, Santarém N, de Sousa A, Borchard G, Junginger HE.
    Eur J Pharm Biopharm; 2008 Jun 08; 69(2):405-16. PubMed ID: 18364251
    [Abstract] [Full Text] [Related]

  • 5. Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B.
    Khatri K, Goyal AK, Gupta PN, Mishra N, Vyas SP.
    Int J Pharm; 2008 Apr 16; 354(1-2):235-41. PubMed ID: 18182259
    [Abstract] [Full Text] [Related]

  • 6. Nanodecoy system: a novel approach to design hepatitis B vaccine for immunopotentiation.
    Goyal AK, Rawat A, Mahor S, Gupta PN, Khatri K, Vyas SP.
    Int J Pharm; 2006 Feb 17; 309(1-2):227-33. PubMed ID: 16406404
    [Abstract] [Full Text] [Related]

  • 7. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery.
    Sayin B, Somavarapu S, Li XW, Thanou M, Sesardic D, Alpar HO, Senel S.
    Int J Pharm; 2008 Nov 03; 363(1-2):139-48. PubMed ID: 18662762
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles.
    Borges O, Tavares J, de Sousa A, Borchard G, Junginger HE, Cordeiro-da-Silva A.
    Eur J Pharm Sci; 2007 Dec 03; 32(4-5):278-90. PubMed ID: 17884394
    [Abstract] [Full Text] [Related]

  • 9. Pharmaceutical and immunological evaluation of mucoadhesive nanoparticles based delivery system(s) administered intranasally.
    Mangal S, Pawar D, Garg NK, Jain AK, Vyas SP, Rao DS, Jaganathan KS.
    Vaccine; 2011 Jul 12; 29(31):4953-62. PubMed ID: 21575664
    [Abstract] [Full Text] [Related]

  • 10. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally.
    Jaganathan KS, Vyas SP.
    Vaccine; 2006 May 08; 24(19):4201-11. PubMed ID: 16446012
    [Abstract] [Full Text] [Related]

  • 11. Polymeric lamellar substrate particles as carrier adjuvant for recombinant hepatitis B surface antigen vaccine.
    Saini V, Sahoo MK, Murthy PK, Kohli D.
    Vaccine; 2009 Apr 14; 27(17):2372-8. PubMed ID: 19428853
    [Abstract] [Full Text] [Related]

  • 12. Cationic transfersomes based topical genetic vaccine against hepatitis B.
    Mahor S, Rawat A, Dubey PK, Gupta PN, Khatri K, Goyal AK, Vyas SP.
    Int J Pharm; 2007 Aug 01; 340(1-2):13-9. PubMed ID: 17446015
    [Abstract] [Full Text] [Related]

  • 13. M-cell targeted delivery of recombinant hepatitis B surface antigen using cholera toxin B subunit conjugated bilosomes.
    Shukla A, Katare OP, Singh B, Vyas SP.
    Int J Pharm; 2010 Jan 29; 385(1-2):47-52. PubMed ID: 19835938
    [Abstract] [Full Text] [Related]

  • 14. Adjuvant effect of CIA07, a combination of Escherichia coli DNA fragments and modified lipopolysaccharides, on the immune response to hepatitis B virus surface antigen.
    Song ES, Park SA, Kim SH, Cho YJ, Ahn BY, Ahn BC, Lee NG.
    FEMS Immunol Med Microbiol; 2007 Dec 29; 51(3):496-504. PubMed ID: 17877731
    [Abstract] [Full Text] [Related]

  • 15. N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model.
    Amidi M, Romeijn SG, Verhoef JC, Junginger HE, Bungener L, Huckriede A, Crommelin DJ, Jiskoot W.
    Vaccine; 2007 Jan 02; 25(1):144-53. PubMed ID: 16973248
    [Abstract] [Full Text] [Related]

  • 16. Immune response induced by a different combined immunization of HBsAg vaccine.
    Wu T, Chen M, Ou SH, Cheng T, Zhang J, Xia NS.
    Intervirology; 2007 Jan 02; 50(5):336-40. PubMed ID: 17700028
    [Abstract] [Full Text] [Related]

  • 17. Intranasal immunization with chitosan/pCETP nanoparticles inhibits atherosclerosis in a rabbit model of atherosclerosis.
    Yuan X, Yang X, Cai D, Mao D, Wu J, Zong L, Liu J.
    Vaccine; 2008 Jul 04; 26(29-30):3727-34. PubMed ID: 18524427
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of the effects of biodegradable nanoparticles on a vaccine delivery system using AFM, SEM, and TEM.
    Kim BG, Kang IJ.
    Ultramicroscopy; 2008 Sep 04; 108(10):1168-73. PubMed ID: 18554804
    [Abstract] [Full Text] [Related]

  • 19. Hepatitis B surface antigen nanoparticles coated with chitosan and trimethyl chitosan: Impact of formulation on physicochemical and immunological characteristics.
    Tafaghodi M, Saluja V, Kersten GF, Kraan H, Slütter B, Amorij JP, Jiskoot W.
    Vaccine; 2012 Aug 03; 30(36):5341-8. PubMed ID: 22749834
    [Abstract] [Full Text] [Related]

  • 20. Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: effect of mucoadhesive coating on antigen uptake and immune adjuvant activity.
    Pawar D, Mangal S, Goswami R, Jaganathan KS.
    Eur J Pharm Biopharm; 2013 Nov 03; 85(3 Pt A):550-9. PubMed ID: 23831265
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.